Trofinetide ( DrugBank: Trofinetide )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
156レット症候群4

156. レット症候群


臨床試験数 : 40 薬物数 : 53 - (DrugBank : 19) / 標的遺伝子数 : 77 - 標的パスウェイ数 : 113
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04988867
(ClinicalTrials.gov)
September 22, 202123/7/2021An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett SyndromeAn Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett SyndromeRett SyndromeDrug: TrofinetideACADIA Pharmaceuticals Inc.NULLRecruiting2 Years5 YearsFemale10Phase 2/Phase 3United States
2NCT04776746
(ClinicalTrials.gov)
November 8, 202029/11/2020Open-Label Extension Study of Trofinetide for Rett SyndromeAn Open-Label Extension Study of Continuing Treatment With Trofinetide for Rett SyndromeRett SyndromeDrug: trofinetideACADIA Pharmaceuticals Inc.NULLEnrolling by invitation5 Years22 YearsFemale153Phase 3United States
3NCT04279314
(ClinicalTrials.gov)
January 29, 202019/2/2020Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett SyndromeA 40-Week, Open-label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett SyndromeRett SyndromeDrug: TrofinetideACADIA Pharmaceuticals Inc.NULLActive, not recruiting5 Years21 YearsFemale180Phase 3United States
4NCT04181723
(ClinicalTrials.gov)
November 6, 201926/11/2019Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Trofinetide for the Treatment of Girls and Women With Rett SyndromeRett SyndromeDrug: Trofinetide;Other: PlaceboACADIA Pharmaceuticals Inc.NULLCompleted5 Years20 YearsFemale187Phase 3United States